A review of adherence to drug therapy in patients with overactive bladder

Basra, Ramandeep; Wagg, Adrian; Chapple, Christopher R.; Cardozo, Linda; Castro-Díaz, David; Pons, Montserrat Espuña; Kirby, Mike; Milsom, Ian; Vierhout, Mark E.; Kerrebroeck, Philip Van; Kelleher, Con

doi:10.1111/j.1464-410x.2008.07769.x

Cited by 139 publications

(121 citation statements)

References 27 publications

(43 reference statements)

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…Poor adherence to medication represents a major c hallenge in patient management. 29 Many factors i nfl uence compliance with therapy including perceived effi cacy, tolerability and the success of conservative methods. It is important to counsel patients regarding the role of medication and to provide information on the side-e ffects, estimated length of treatment, other therapies available, how the medication will improve their symptoms, and how long it may take to be able to notice these differences.…”

Section: Smoking Cessationmentioning

confidence: 99%

Diagnosis and management of the overactive bladder syndrome in women

Rantell

Cardozo

2009

Trends Urology, Gynecol. Sexual Health

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Smoking Cessationmentioning

confidence: 99%

Diagnosis and management of the overactive bladder syndrome in women

Rantell

Cardozo

2009

Trends Urology, Gynecol. Sexual Health

Self Cite

View full text Add to dashboard Cite

show abstract

“…There are various evaluation methods, such as pill counting, measurement of the blood drug concentration, interview-based evaluations by physicians and self-rating scales. All of these methods have advantages and disadvantages [12]. Pill counting lacks reliability because the ingestion of drugs cannot be confirmed [13].…”

Section: Introductionmentioning

confidence: 99%

Reliability and Validity of the Japanese Version of BEMIB Modified for Patients With Bipolar Disorder: a Self-rating Scale for Medication Adherence

Tokura

德倉

2012

CNPT

View full text Add to dashboard Cite

Purpose: Accurate evaluation of medication adherence is important; however, no simple evaluation scale that is applicable to patients with bipolar disorder has been established in Japan. In this study, we prepared a modified Japanese version of a self-rating scale for medication adherence in the field of psychiatry, the Brief Evaluation of Medication Influences and Beliefs (BEMIB), and investigated its reliability and validity. Methods: Forty-one patients with bipolar disorder who visited several facilities, including Nagoya University Results:The Cronbach α coefficient of the Japanese version of BEMIB was 0.73. Four-week test-retest reliability coefficients of each item and the BEMIB total score were 0.39-0.68 (p < 0.05) and the intra-class correlation coefficient was 0.63 (95% CI = 0.33-0.75, p < 0.001). In addition, a significant positive correlation was observed between the BEMIB and DAI-10 total scores (Pearson's correlation coefficient = 0.39, p < 0.001), showing that the concurrent validity was sufficient. Discussion: The Japanese version of BEMIB modified for patients with bipolar disorder is sufficiently reliable and valid. We suggest that this simple evaluation scale of medication adherence in patients with bipolar disorder is applicable in routine medical practice.

show abstract

“…Compliance and satisfactory results, however, are low after 1 year and range from 18% to 65%. 6,7 Patients with medication refractory OAB have the option of sacral neuromodulation (SNM), intravesical injection of Botulinum Toxin type A (BTX A) or surgery, such as bladder augmentation or diversion.I strongly belief the most appropriate option for these patients is SNM. It is the most innovative treatment modality developed in recent years for the management of OAB and other voiding dysfunctions; it has also been approved by Health Canada for this indication since 1999.…”

mentioning

confidence: 99%

mentioning

confidence: 99%

Patients with medication-refractory OAB symptoms should be further treated with neuromodulation

Gajewski

2011

cuaj

View full text Add to dashboard Cite

O veractive bladder (OAB) is a condition defined by the International Continence Society (ICS) as urgency with or without urgency incontinence, usually with increased daytime frequency and nocturia. 1 Patients with OAB have significantly reduced quality of life.2 Population-based surveys done in Canada have shown high prevalence (14%) in both sexes.3 In a survey of over 19 000 adults in Canada and Europe, the overall prevalence of OAB was 12.8% in women and 10.8% in men. 4 The similar study in United States showed that overall, 16.5% of the U.S. population aged ≥18 years (about 33 million people) have symptoms of OAB. 5 The initial treatment of the OAB includes anticholinergic medications. Compliance and satisfactory results, however, are low after 1 year and range from 18% to 65%. 6,7 Patients with medication refractory OAB have the option of sacral neuromodulation (SNM), intravesical injection of Botulinum Toxin type A (BTX A) or surgery, such as bladder augmentation or diversion.I strongly belief the most appropriate option for these patients is SNM. It is the most innovative treatment modality developed in recent years for the management of OAB and other voiding dysfunctions; it has also been approved by Health Canada for this indication since 1999. The ideal treatment should be effective, safe and financially sound. There is no question that SNM is effective. Brazzelli and colleagues systematic review found that 80% (4 randomized controlled trials) and 67% (30 case series) of patients became dry or achieved a >50% improvement in symptoms after implantation. 8 Our own data showed 84.8% success rate with a median follow-up of 50 months (Fig. 1). 10 Furthermore, in a recent study, overall satisfaction was reported as high as 90%.9 There are very little initial complications with the device. The infection rate is under 5%; in our series of 96 implants, no infection was reported at all. There is a possibility of seroma formation which was described occasionally. In our experience, the reoperation rate due to malfunction of the device or lack of improvement was initially high at 40%. The main reason for revisions (50%) was poor response. The second most common indication (17%) for revision was local pain from the device. The median time for revision was 24 months. Review of the literature of 855 patients, showed 33% revision rate. Most of the studies, including ours, consist of sacral nerve stimulation non-tined lead data, which have higher complication rates associated with the open fasciotomy procedure and lead migration. 10With the advances in the equipment and surgical technique, this rate was reduced to 26% with a combined revision rate of 32% in our experience. The biggest improvement was in the introduction of the tined-lead which can be implanted through percutaneus, minimal invasive technique. Some patients also complained of unpleasant sensations or pain. This, however, was usually resolved with reprogramming. Patients are followed on a regular basis the third and sixth month mark, and then yearly. The ...

show abstract

A review of adherence to drug therapy in patients with overactive bladder

Cited by 139 publications

References 27 publications

Diagnosis and management of the overactive bladder syndrome in women

Diagnosis and management of the overactive bladder syndrome in women

Reliability and Validity of the Japanese Version of BEMIB Modified for Patients With Bipolar Disorder: a Self-rating Scale for Medication Adherence

Patients with medication-refractory OAB symptoms should be further treated with neuromodulation

Contact Info

Product

Resources

About